MNPR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.6M
+27.2%
5.2M
-15.1%
6.2M
+50.4%
4.1M
+26.6%
3.2M
R&D
4.8M
+36.7%
3.5M
-11.5%
3.9M
+52.2%
2.6M
+49.7%
1.7M
SG&A
1.9M
+8.0%
1.7M
-21.5%
2.2M
+47.3%
1.5M
-0.1%
1.5M
Operating Income
-6644663
-27.2%
-5225253
+15.1%
-6155228
-50.4%
-4093075
-26.6%
-3234295
EBITDA
-6644663
-27.2%
-5225253
+15.1%
-6155228
-50.4%
-4093075
-26.6%
-3234295
Net Income
-5313300
-36.5%
-3893050
+25.1%
-5200794
-51.3%
-3437602
-40.1%
-2453526
EPS (Basic)
$-0.62
-34.8%
$-0.46
+24.6%
$-0.61
-27.1%
$-0.48
-37.1%
$-0.35
EPS (Diluted)
$-0.62
-34.8%
$-0.46
+24.6%
$-0.61
-27.1%
$-0.48
-37.1%
$-0.35
Shares (Diluted)
8.5M
+0.1%
8.5M
+0.0%
8.5M
+19.8%
7.1M
+1.8%
7.0M
Monopar Therapeutics (MNPR) โ€” Financials